(LONN) Lonza - SW
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: SW (Switzerland) | Market Cap: 34.454m CHF | Total Return: -11.2% in 12m
Avg Turnover: 67.0M
Warnings
Choppy Below Avwap Earnings
Tailwinds
Confidence
Lonza Group AG is a Switzerland-based contract development and manufacturing organization (CDMO) providing end-to-end services for the pharmaceutical and biotechnology industries. The company operates through three primary segments: Integrated Biologics, Advanced Synthesis, and Specialized Modalities, covering a broad spectrum of therapeutic technologies including mammalian cell cultures, small molecules, and cell and gene therapies.
The CDMO business model relies on high capital expenditure and specialized technical expertise, allowing pharmaceutical clients to outsource complex manufacturing while reducing their own infrastructure costs. Lonzas portfolio includes high-growth areas such as antibody-drug conjugates (ADCs) and mRNA, which require stringent regulatory compliance and advanced cleanroom environments. To better understand the companys valuation and growth trajectory, you may wish to examine the detailed metrics available on ValueRay.
Founded in 1897, Lonza maintains a global footprint with operations across Europe, the Americas, and Asia-Pacific. As a large-cap entity in the healthcare sector, its revenue streams are diversified across various drug platforms, ranging from early-stage clinical development to large-scale commercial production.
- Biologics segment revenue grows on large-scale mammalian manufacturing demand
- ADC and bioconjugates capacity expansion drives Advanced Synthesis margins
- Cell and gene therapy pipeline maturation scales Specialized Modalities revenue
- Capital expenditure for Vacaville site acquisition impacts free cash flow
- Biotech funding environment volatility influences early-stage clinical service demand
| Net Income: 909.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -0.66 > 1.0 |
| NWC/Revenue: 67.82% < 20% (prev 28.31%; Δ 39.51% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.17b > Net Income 909.0m |
| Net Debt (3.82b) to EBITDA (1.81b): 2.11 < 3 |
| Current Ratio: 2.24 > 1.5 & < 3 |
| Outstanding Shares: last quarter (70.2m) vs 12m ago -3.47% < -2% |
| Gross Margin: 34.63% > 18% (prev 32.86%; Δ 1.78% > 0.5%) |
| Asset Turnover: 33.75% > 50% (prev 33.31%; Δ 0.44% > 0%) |
| Interest Coverage Ratio: 6.99 > 6 (EBIT TTM 1.17b / Interest Expense TTM 167.0m) |
| A: 0.23 (Total Current Assets 8.00b - Total Current Liabilities 3.57b) / Total Assets 19.0b |
| B: 0.52 (Retained Earnings 9.92b / Total Assets 19.0b) |
| C: 0.06 (EBIT TTM 1.17b / Avg Total Assets 19.4b) |
| D: 0.93 (Book Value of Equity 9.13b / Total Liabilities 9.78b) |
| Altman-Z'' = 4.62 = AA |
| DSRI: 1.14 (Receivables 1.78b/1.57b, Revenue 6.53b/6.57b) |
| GMI: 0.95 (GM 32.86% / 34.63%) |
| AQI: 0.48 (AQ_t 0.14 / AQ_t-1 0.29) |
| SGI: 0.99 (Revenue 6.53b / 6.57b) |
| TATA: -0.01 (NI 909.0m - CFO 1.17b) / TA 19.0b) |
| Beneish M = -3.27 (Cap -4..+1) = AA |
As of June 20, 2026, the stock is trading at CHF 491.60 with a total of 176,860 shares traded.
Over the past week, the price has changed by -0.08%,
over one month by +4.98%,
over three months by +3.17% and
over the past year by -11.23%.
Lonza has no consensus analysts rating.
P/E Trailing = 37.9462
P/E Forward = 27.6243
P/S = 5.2755
P/B = 4.3638
P/EG = 1.4529
Revenue TTM = 6.53b CHF
EBIT TTM = 1.17b CHF
EBITDA TTM = 1.81b CHF
Long Term Debt = 3.88b CHF (from longTermDebt, last quarter)
Short Term Debt = 309.0m CHF (from shortTermDebt, last quarter)
Debt = 4.54b CHF (from shortLongTermDebtTotal, last quarter) + Leases 355.0m
Net Debt = 3.82b CHF (calculated: Debt 4.54b - CCE 719.0m)
Enterprise Value = 38.3b CHF (34.5b + Debt 4.54b - CCE 719.0m)
Interest Coverage Ratio = 6.99 (Ebit TTM 1.17b / Interest Expense TTM 167.0m)
EV/FCF = -180.5x (Enterprise Value 38.3b / FCF TTM -212.0m)
FCF Yield = -0.55% (FCF TTM -212.0m / Enterprise Value 38.3b)
FCF Margin = -3.25% (FCF TTM -212.0m / Revenue TTM 6.53b)
Net Margin = 13.92% (Net Income TTM 909.0m / Revenue TTM 6.53b)
Gross Margin = 34.63% ((Revenue TTM 6.53b - Cost of Revenue TTM 4.27b) / Revenue TTM)
Gross Margin QoQ = 32.83% (prev 36.13%)
Tobins Q-Ratio = 2.02 (Enterprise Value 38.3b / Total Assets 19.0b)
Interest Expense / Debt = 3.68% (Interest Expense 167.0m / Debt 4.54b)
Taxrate = 17.44% (192.0m / 1.10b)
NOPAT = 964.3m (EBIT 1.17b * (1 - 17.44%))
Current Ratio = 2.24 (Total Current Assets 8.00b / Total Current Liabilities 3.57b)
Debt / Equity = 0.50 (Debt 4.54b / totalStockholderEquity, last quarter 9.13b)
Debt / EBITDA = 2.11 (Net Debt 3.82b / EBITDA 1.81b)
Debt / FCF = -18.02 (negative FCF - burning cash) (Net Debt 3.82b / FCF TTM -212.0m)
Total Stockholder Equity = 9.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.70% (Net Income 909.0m / Total Assets 19.0b)
RoE = 9.98% (Net Income TTM 909.0m / Total Stockholder Equity 9.11b)
RoCE = 9.00% (EBIT 1.17b / Capital Employed (Equity 9.11b + L.T.Debt 3.88b))
RoIC = 6.27% (NOPAT 964.3m / Invested Capital 15.4b)
WACC = 6.95% (E(34.5b)/V(39.0b) * Re(7.46%) + D(4.54b)/V(39.0b) * Rd(3.68%) * (1-Tc(0.17)))
Discount Rate = 7.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -76.41 | Cagr: -2.61%
[DCF] Fair Price = unknown (Cash Flow -212.0m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 64.62 | Revenue CAGR: 12.66% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=18.23 | Chg30d=+0.66% | Revisions=+38% | GrowthEPS=+21.3% | GrowthRev=+9.1%
EPS next Year (2027-12-31): EPS=21.80 | Chg30d=+0.67% | Revisions=+43% | GrowthEPS=+19.6% | GrowthRev=+12.0%
[Analyst] Revisions Ratio: +43%